<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00695344</url>
  </required_header>
  <id_info>
    <org_study_id>EVEROSTAT</org_study_id>
    <nct_id>NCT00695344</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Effect of Everolimus in Progression of Graft Vascular Illness on Patients With Heart Transplant</brief_title>
  <acronym>EVEROSTAT</acronym>
  <official_title>Prospective and Randomized Study to Evaluate the Effect of Everolimus in the Clinical and Intra-Cardiac Ecography Progression of Heart Graft Vascular Illness.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion Investigacion y Desarrollo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion Investigacion y Desarrollo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate if there is a significantly less incidence of major
      clinical events due to graft vascular illness in recipients of a cardiac transplant on
      treatment with an immunosuppressive combination, which includes Everolimus, compared to those
      that continue the previously used immunosuppressive treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, multicentre, open and controlled study, to evaluate the
      efficacy and safety of everolimus combined with cyclosporin for microemulsion and steroids
      according to medical judgement, opposite to the usual therapy which the patient already has
      received (typically: ciclosporin + azathioprine or mycophenolate mofetil + steroids according
      to the judgement of the doctor) for patients receiving a cardiac orthotopic transplant since
      at least 12 months. The patients will be randomized in a 2:1 proportion (everolimus:control),
      in order to make it possible for the majority of patients to receive the potentially active
      treatment in a lethal illness for which there is not efficient known treatment up to date.

      The study duration will be 2 years of follow-up for each patient. At the end of this period,
      the patients will be offered the possibility to maintain the immunosuppressive treatment to
      which they have been assigned, and periodic revisions will be made each 3-6 months.

      The two treatment groups are:

      Group I - Everolimus twice a day v.o. + cyclosporin for microemulsion in reduced doses +/-
      steroids.

      Group II - Cyclosporin for microemulsion + azathioprine or mycophenolate mofetil +/- steroids
      (the same administration schedule and medication which the patient received earlier).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2006</start_date>
  <completion_date type="Anticipated">June 2010</completion_date>
  <primary_completion_date type="Anticipated">June 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects that present at least one major clinical event due to graft vascular illness during the first year of the study on both treatment arms.</measure>
    <time_frame>December 2010</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intra-coronary ultrasound, safety and adverse events, Nt-proBNP, left ventricular systolic function, coronary stenosis.</measure>
    <time_frame>December 2010</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Cardiac Transplant</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Everolimus 2 times per day + cyclosporin low dose +/- steroids</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cyclosporin + azathioprine or mofetil mycophenolate +/- steroids (the same treatment that patient had before the study).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>everolimus</intervention_name>
    <description>Everolimus 2 times per day, v.o., 2 years treatment.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Certican</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azathioprine or mycophenolate mofetil</intervention_name>
    <description>2 times per day during 2 years</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Imurel</other_name>
    <other_name>Cellcept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients suffering a heart transplantation at least 12 months before the inclusion.

          -  Patients with significant graft vascular cardiac illness.

        Exclusion Criteria:

          -  Patients who received more than one solid organ.

          -  Hypersensibility to everolimus.

          -  Patients with expected surviving less than 6 months.

          -  Analytic abnormality significant (platelets &lt; 70.000 plat./mm3, WBC&lt;4.000./mm3,
             creatinine &gt; 2,5 mg/dl)

          -  Neoplasm and/or severe systemic illness.

          -  Mental significant illness.

          -  Patients who have received sirolimus or everolimus in any moment after transplant.

          -  Pregnant or lactating woman.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javier Segovia, cardiologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Puerta de Hierro</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicolás Manito, Cardiologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari de Bellvitge</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gregorio Rábago, Cardiologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clínica Universitaria de Navarra</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francisco González-Vílchez, Cardiologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Marqués de Valdecilla</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan Delgado, Cardiologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital 12 de Octubre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan Fernández Yañez, Cardiologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Gregorio Marañón</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sonia Mirabet, Cardiologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eulalia Roig, Cardiologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <zip>28035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2008</study_first_submitted>
  <study_first_submitted_qc>June 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2008</study_first_posted>
  <last_update_submitted>January 29, 2009</last_update_submitted>
  <last_update_submitted_qc>January 29, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Javier Segovia</name_title>
    <organization>Hospital Puerta de Hierro</organization>
  </responsible_party>
  <keyword>Effect of everolimus in graft vascular cardiac illness</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

